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herapeutic HIV vaccines: Prior setbacks, current advances, and
uture prospects
. Introduction
Soon after HIV was ﬁrst identiﬁed as the cause of AIDS, studies
egan toexplorewhether therapeutic vaccinationmighthavea role
n slowing or preventing the progression of disease. On September
9th and 20th, in Bethesda, Maryland, USA, AVAC and Treatment
ction Group, in collaboration with the Timely Topics series of the
lobal HIV Vaccine Enterprise, convened a workshop of over 100
esearchers, funders, and advocates to discuss current issues in
herapeutic HIV vaccine research and development. The meeting
as organized around a series of presentations followed by break-
ut groups to discuss and identify recommendations for the ﬁeld.
he purpose of this paper is to delineate the presentations andﬁnd-
ngs that emerged from the meeting from the perspective of the
rganizers with the goal of accelerating and enhancing the search
or therapeutic HIV vaccines capable of suppressing viral repli-
ation and preventing disease progression. Over two days there
ere 23 presentations and four breakout sessions, all of which
ontributed to contents and conclusions of this paper. One theme
hroughout the meeting was the intersection of therapeutic and
reventive vaccine research. Presentations by Drs. Harriet Robin-
on, Chil-Yong Kang, Pablo Tebas and Carol Weiss addressed the
essons that could be learned from preventive vaccines, and iden-
iﬁed opportunities for collaboration between the two ﬁelds.
The meeting began with a presentation by Dr. Yves Levy on the
cientiﬁc rationale for therapeutic vaccines. The initial impetus for
tudying therapeutic HIV vaccines was based on the early, widely
eld view that HIV remained latent for a prolonged period before
ventually emerging to causeAIDS. If therewas aperiodof viral qui-
scence, it was reasoned, it might allow for bolstering HIV-speciﬁc
mmunity and enhance prospects for continued viral containment
ith vaccination [1]. Enthusiasm for the idea has ebbed and ﬂowed
ver the years, with initial optimism eroded by largely disappoint-
ng results from early clinical trials. Interest also declined with
oth the welcomed success of the modern antiretroviral therapy
ART) era with its ability to control viral load and transmission,
nd the sobering ﬁnding that HIV compromises the immune sys-
em early in infection and continues to progressively damage it due
o ongoing viral replication during the asymptomatic period [2].
ecent developments have provided new reasons to more rigor-
usly pursue therapeutic HIV vaccine research. Chief among them
s the renewed focus on curing HIV infection, and evidence from
n vitro studies suggesting that therapeutic vaccination might be
ble to contribute to clearance of virus persisting in the presence
f ART, which suppresses viral load but does not eliminate latent
iral reservoirs [3].
Drs. Galit Alter, Vidar Wendel-Hansen, Lucy Dorrell and Mike
cCune discussed the immunologic responses that they believe
ttp://dx.doi.org/10.1016/j.vaccine.2014.06.066
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article uwill be necessary for therapeutic HIV vaccines. Recent research
indicates that there may be previously unexplored opportunities
for manipulating immune responses, such as harnessing emerging
information about innate immunity to develop improved vaccine
adjuvants [4], exploiting antibody effectormechanisms [5–7], anti-
immune activation or exhaustion approaches [8,9], and regulatory
T cell responses [10]. Inmany cases, interest in these areas overlaps
work that is underway in the preventive vaccine ﬁeld.
The advent of combination ART largely shifted the goals of
therapeutic vaccination toward delaying, simplifying or allowing
intermittent ART treatment, although these objectives have var-
ied depending on setting and the associated feasibility of access to
lifelong ART. Overall, however, results from clinical trials of can-
didate therapeutic vaccination approaches have not shown clear
clinical beneﬁt [11,12]. A multitude of possible reasons have been
suggested to explain the lack of success, including: vaccines may
simply boost the ineffective immune responses fromwhichHIVhas
largely escaped [13], early depletion of CD4T cells particularly from
gut [14], and/or preferential infection and deletion of HIV-speciﬁc
CD4T cells [15].Moreover, ﬁbrotic damage to lymphnode architec-
ture [16] impairs the induction of new immune responses and/or
fosters immune exhaustion/senescence [17,18].
2. Virology and immunology
Because thenatural immune responses inducedbyHIV infection
rarely effectively control HIV replication, an effective therapeutic
vaccinewill likely need to elicit immune responses that are qualita-
tively different from those that emergeduring typical, uncontrolled
HIV infection. Knowledge regarding rare individuals who sponta-
neously control HIV replication in the absence of treatment (“elite
controllers”) might be informative and substantial resources have
been aimed at studying their immune responses [19]. Controllers
generally have strong HIV-speciﬁc CD8 and perhaps CD4 func-
tions that target conserved regions, although there are exceptions
[10,20]. It is unclear, however, whether such responses are sufﬁ-
cient for control, and given the apparent contribution of favorable
MHC Class I alleles to such responses in at least some controllers,
whether suchmechanisms can be generalized to the broader popu-
lation level. Indeed, host genetic association studies suggest that a
combination of T cell and innate (e.g., NK cells) responses might
be required [21]. Neutralizing antibodies do not appear to be
associated with control, although there are some emerging data
suggesting that antibody-dependent cell-mediated cytotoxicity
[22] (ADCC) may contribute to control in at least some individuals.
Many other potential mechanisms have been suggested for elite
control (e.g., reduced viral ﬁtness [23], cellular restriction [24], sus-
tained T cell survival [25]), but these mechanisms have not been
effectively translated to a therapeutic setting.
Given the robust association between CD8 T cell function
and control in natural infection [26], much of the emphasis in
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Fig. 1. A combination of multiple approaches may be required for improved viral
control or cure. Compounds such asHDAC inhibitors are tested as away to reactivate
latent viruses andmake themvisible to the immune system. Anti-exhaustion strate-
gies, such as anti-PD1 antibodies, seek to stimulate existing anti-viral responses.
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oaccination strategies re-focus immune responses on more vulnerable parts of the
irus, while stimulating direct or antibody-dependent killing of infected cells by
D8+ lymphocytes.
herapeutic vaccine research has understandably focused on gen-
rating potent and sustained CD8 antiviral activity in ART-treated
ndividuals. This has proven challenging as most vaccines studied
o date appear to simply increase the pre-existing immunodom-
nant clones. Such cells are either exhausted or target regions of
he virus that have already escaped. For this reason, strategies
edirecting responses to subdominant conserved CTL epitopes are
ursued [27]. Also many studies are now focused on individuals
uring acute infection, before onset of irreversible immune dys-
unction and/or viral escape. Only recently therapeutic vaccine
pproaches, which induce humoral responses and marshal innate
mmunity such as NK cells, have been considered as an alternative
r adjunct to cytotoxic T cells (Fig. 1) [5,12,28].
Assessment of vaccine-induced immune responses can be
chieved through a range of T cell, B cell, and innate immunity
ssays. Many of the same assays and reagents used to develop pre-
entive vaccines can be applied to therapeutic vaccine research.
owever, there is no consensus on assays that would allow for trial
omparisons, and on methods to address biological variability in
aseline viral load and other responses in HIV positive individuals.
ne promising and relatively new approach is the measurement
f the ability of HIV-speciﬁc CD8 T cells to kill infected CD4 T cell32 (2014) 5540–5545 5541
targets, which is just beginning to be evaluated in the context of
vaccine trials [29,30].
Given the focus on curative interventions, a primary outcome
measure in most modern therapeutic vaccines studies is the size
of the “latent reservoir”, perhaps best deﬁned as the residual
virus that remains in the setting of apparently effective combina-
tion ART, and is able to give rise to recrudescent viral replication
and progressive disease after ART is stopped. At least part of
this “reservoir” is composed of virus in latently infected cells,
rather than actively replicating virus. Although viral outgrowth
assays used to quantify the replication-competent reservoir are
viewed as the gold standard, there is no current standard, high-
throughput measure of the reservoir. Measures of plasma HIV
RNA, cell-associated HIV RNA (unspliced, multiply spliced) and
cell-associated DNA (integrated, unintegrated, total) are being
developed, but these are unlikely to fully resolve the difﬁculties of
distinguishing replication-competent latentproviruses fromdefec-
tive ones [31]. Measurement of the HIV reservoir both in vitro
and in vivo has emerged as an important potential biomarker
that will require additional development and optimization
[32,33].
3. Clinical trials of therapeutic vaccines
Drs. Nicole Frahm, Felipe Garcia, Jeff Jacobson, John Eldridge,
Jean Boyer and George Pavlakis discussed the lessons that can be
learned from past therapeutic vaccine studies in humans (Fig. 2).
Therapeutic vaccine candidates recently tested have utilized a vari-
ety of platforms and approaches includingDNA, viral vectors (alone
and with DNA) [34–36] dendritic cells (DC) [37,38] and peptides
[27,39,40], using a variety of antigens together in some case with
adjuvants and immune modulators. A few clinical trials of ther-
apeutic vaccines to date have induced a transitory reduction in
viral load in the context of treatment interruption. Some of these
trials have shown modest delays in time to viral load rebound,
prolongation of time until ART needs to be resumed, and/or sus-
tained reductions of viral load (typically less than 0.5 log10 copies
RNA/mL) [12]. Although these reductions are of unknown clinical
beneﬁt, they suggest that therapeutic vaccines might have a role
in reducing viral load for clinical beneﬁt or as part of an HIV cure.
Recent clinical studies have looked at the impact of vaccination on
latently infected resting CD4+ T cells ﬁnding no effect with DNA
vaccination [41] and a modest decrease with CD4+ IFNy and Il-2
responses after MVA fowl pox vaccination [42]. Presentations by
Drs. Steven Deeks, Jonathan Karn, Lucy Dorrell and George Pavlakis
addressed the question of the role of therapeutic vaccine research
in the HIV cure agenda.
Some recent studies have focused on stimulating dendritic
cell function, usually with autologous viruses and more recently
with HIV lipopeptides. A trial of autologous monocyte-derived-DC
pulsed with inactivated autologous HIV has shown a correlation
between the T cell responses and viral load and CD4+ cells levels
after ART interruption [38]. The use of autologous dendritic cells
electroporatedwith in vitro transcribed RNA encoding the patient’s
own HIV antigens has been reported to be potentially effective in
reducing viral load set point [39].
Presentations by Dr. Jeff Lifson and Dr. George Pavlakis focused
on past therapeutic vaccine studies in non-human primates (NHP).
Preclinical studies of therapeutic vaccines in NHP models provide
a useful approach for assessing safety, immunogenicity and efﬁ-
cacy of different vaccine modalities, conferring advantages such
as control over experimental parameters such as timing of infec-
tion and ART initiation [40]. Recently reported results from NHP
trial of a preventive CMV-based vaccine showed that vaccination
could lead to a signiﬁcant improvement in viral control and even
5542 Conference report / Vaccine 32 (2014) 5540–5545
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tig. 2. Listing of Phase I, II or III clinical trials from 2008 to 2014 testing therapeut
latform.
llowcomplete viral clearance [43,44]. Interestingly, in light of con-
erns that conventional therapeutic vaccinesmayprimarily expand
esponses that are exhausted or target epitopes that have already
scaped, there are some indications that efﬁcacyof this vaccinemay
e attributed to unique ability of the vector to generate novel CD8+
cell responses targeting a range of non-canonical epitopes (rather
han expanding typical, limited immunodominant responses) [45].
s these live viral vectors persist, large numbers of effector cells are
ontinually maintained. An alternative approach of DNA vaccina-
ion has resulted in modest control of viremia in both prophylactic
nd therapeutic NHP studies [46–48].
The therapeutic vaccineﬁeldhas begun to consider combination
pproaches to increase the breadth and functionality of immune
esponses using novel immunomodulatory biologics that are hav-
ng profound effects on the treatment of cancer (Fig. 1). There is
ntense interest in an entire family of antibodies that reverse the
egative regulatoryeffectsof PD-1, CTLA-4, LAG-3 [49,50] andother
ntracellular pathways. Combinations of therapeutic vaccines and
arly treatment to preserve immune function are also being consid-
red. [51]. These approaches would aim to activate latent virus and
se vaccine-induced responses to eliminate the infected cells. NHP
tudies may be well suited to test these “Shock and Kill” combi-
ation strategies [52,53]. Some preliminary evidence also suggests
hat therapeutic vaccines themselves may be able to activate at
east some latent virus by stimulating infectedmemory CD4 T cells
hat are HIV-speciﬁc [34,54].vaccines by sponsor, phase, trial site location, number of participants and vaccine
4. Clinical trial design and regulatory challenges
Therapeutic vaccine development for individuals under ART
treatment poses particular challenges for clinical trial design. Spe-
ciﬁc issues include: safe use of analytical treatment interruptions
(ATI) in clinical trials, identiﬁcation of clinically relevant biomark-
ers, assays to measure the HIV reservoir [55,56], and potential
differences in the optimal use of therapeutic vaccine approaches
for different populations.
Dr. Carol Weiss in her presentation highlighted the fact that
there is limited regulatory precedent for approved therapeutic
vaccines. The antiviral effect of therapeutic HIV vaccines is difﬁcult
to measure during ART and the immune correlates of therapeutic
beneﬁt are unknown. Since there is now limited tolerance from
an individual or public health perspective for allowing the virus to
persist in a readily detectable manner, the era in which vaccines
might be used to simply partially control HIV or delay time to ART,
without showing a clinical beneﬁt, has passed [57]. Therapeutic
vaccines which result in safe, sustained, control of viral replication
comparable to that achieved with accessible standard ART could
possibly meet with regulatory approval, but this is a high standard
that will be extraordinarily difﬁcult to achieve. A more feasible
outcome with a vaccine might be partial clearance of the reservoir
during ART, but the clinical beneﬁt of this is unknown. An ultimate
objective would be an intervention, including therapeutic vacci-
nation performed during ART, which would result in sufﬁcient
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iminishment of residual virus and control of viral replication as
o allow discontinuation of ART.
. Next steps
With over 35 million people living with HIV [58], the develop-
ent of a safe, effective, and accessible HIV therapeutic vaccine
apable of either clearing reservoir during ART (presumably as a
omponent of a combination cure strategy) or causing sustained
ontrol of virus in absence of ART represents a highly desirable
lobal public health goal. The focus on elucidating mechanisms
r markers of control and elimination of virus must sharpen.
ew information should come from a variety of sources, includ-
ngNHP experiments, studies of natural infection, and clinical trials
especially experimental medicine trials to identify mechanisms of
athogenesis, or to demonstrate proof-of-concept). The required
mmune responseand therapeutic beneﬁt fromtherapeutic vaccine
emains an area of discussion and debate. At the same time, there
re promising areas of scientiﬁc focus and strategic approaches that
ould accelerate the development of a therapeutic vaccine.
The current pipeline of candidates for clinical trial should be
adjusted with emphasis on iterative improvement of the most
promising candidates. Because available resources are limited,
this will require coordinated decision-making by funders and
research groups, likely at the cost of testing a smaller total num-
ber of candidates. In the process, it will be important not to stiﬂe
innovation and to continue encouraging vaccine concepts with
distinct immunological proﬁles. The ﬁeldmay learn from the pre-
ventive HIV vaccines, where the Immune Space Template [http://
www.vaccineenterprise.org/immunespace] has been designed
for a more rational comparison and prioritization of candidates.
Fig. 3. Public agencies, non-governmental organizations, and private compan32 (2014) 5540–5545 5543
• Simply boosting immune responses found in natural infection
will likely be ineffective because of viral escape. A successful ther-
apeutic vaccinewouldneed to induce responses to conserved and
subdominant epitopes that areusuallynot recognizedduringnat-
ural infection. Proven ability of a vaccine to elicit responses to
these regions (either in humans or in NHPs) may also serve as a
key criterion for advancement and prioritization of candidates in
the pipeline.
• It will be important to explore vaccines that aim to employ
immune mechanisms not explicitly targeted in previous studies.
• Of special interest are therapeutic modalities that rationally seek
to overcome limitations of simply expanding pre-existing HIV-
speciﬁc T cells. The approaches may include combination with
latency activators to stimulate production of virus, which will
expand host responses and target infected cells for clearance.
• Immunomodulatory drugs that enhance T cell function should
also be considered. These approaches might include antibody
therapies that reverse immune exhaustion (e.g., anti-PD-1 anti-
bodies) or adjuvants that speciﬁcally replace aspects of immune
function altered by HIV (e.g., co-expression of CD40L, GM-CSF).
• Since the range of baseline immune functions is signiﬁcantly
more variable in people living with HIV on ART than in HIV-
negative people, studies aimed at deﬁning and overcoming this
variability via development of new and/or adaptation of existing
assays and statistical approaches will be necessary for deﬁnitive
monitoring and endpoint assays in clinical trials.
• The value of NHP studies in testing hypotheses and understand-
ingmechanisms iswidely acknowledged.However, resources are
needed to resolve outstanding issues in use of NHP models, such
as development of effective ART regimens, optimal challenge
viruses, andmissing reagents for studying immune responses. For
thesemodels to be optimal, the effectiveness of viral suppression
ies investing in 2012 research into therapeutic HIV vaccines by country.
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should be comparable to that in typicalwell-treatedHIV-infected
individuals.
Collaboration is needed to achieve consensus among researchers,
clinicians, and community on safe and informative ATI stud-
ies. Challenges in this area include the long-standing concern
about the inﬂammation associated with unchecked HIV replica-
tion and the risk for development of drug resistance, as well as
newly emergingworries about the impact such interruptionswill
have on the size of latent reservoirs of the virus. Sensitive virus-
detection assayswithmechanisms for timely reinstitution of ART
provide the opportunity to monitor viral rebound at levels that
are unlikely to negatively impact the health of volunteers.
Because of biological and risk/beneﬁt considerations, the design
of therapeutic vaccine candidates may and, arguably, should be
different frompreventive vaccines. Strategies to enhance vaccine
responses in the therapeutic context should be informed by the
accumulated knowledge about HIV pathogenesis and its impact
on the immune system.
Discussions among researchers, clinicians, and regulators are
needed to achieve consensus on appropriate end points in clin-
ical trials of therapeutic vaccines. It remains to be determined
what immunological, virological, or clinical outcomes canbeused
to justify advanced clinical development of therapeutic vaccine
candidates. Elucidating these outcomes will be instrumental in
regulatory approval and deployment of a therapeutic vaccine.
Prioritization should be on strategies that can be scaled up
to address the global impact of HIV infection, while seriously
considering the cost, implementation, and clade speciﬁcity of the
potential ﬁnal product.
. The future
Rather than retreating in the face of the problems, therapeutic
accination and development efforts – both privately and publicly
unded – have continued (Fig. 3). The evidence that a therapeutic
accine approachmay be able to contribute to achieving a cure has
ow added impetus to efforts to reﬁne and improve therapeutic
accine candidates. At the same time, scientiﬁc progress in under-
tanding HIV latency and in design of therapeutic vaccines that
odestly and temporarily reduce viral load provides an opportu-
ity to begin to solve the problems that have impeded achieving
igniﬁcant clinical beneﬁt.
The therapeutic vaccine ﬁeld lies on the intersection of several
ctive areas of HIV research: preventive vaccines, treatment, and
ure. Active linksmust be encouragedbetween researchers in those
elated ﬁelds through productive collaborations and common dis-
ussion to share ideas, latest discoveries, and resources. Work by
esearchers, funders and advocates remains critically important for
ncreasing awareness and understanding regarding the new era
n therapeutic vaccine research and the possibility of ultimately
eneﬁtting public health.
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